If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing preeclampsia. This particular type of drug, however, originally received an X designation by the FDA. An X designation is given when, “Studies in animals or humans have demonstrated fetal abnormalities…and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.” The X classification for pravastatin was based primarily on the fact that there was no known indication for use in pregnancy, and therefore any possible risk outweighed benefit. There was also some concern about fetal anomalies, but the latter was not confirmed in follow-up studies.
The current study followed-up children involved in two small pilot studies where women were randomly assigned to take pravastatin or placebo for preeclampsia prevention. Both studies were too small to document a significant decrease in the incidence of preeclampsia, but did show that doses of 10 and 20 mg were well-tolerated and there were no short-term adverse effects on the pregnant persons or their newborns. Researchers were able to examine 30 of the 40 children born during these two studies at an average age of 4.7 years of age. The children underwent extensive neuro-developmental testing. In addition, medical examinations were conducted, including height and weight, and information collected about medical history, vision problems, & hearing loss. There were no differences between those exposed to pravastatin and those who were not.
Take home: Based on limited data, pravastatin use during pregnancy does not appear to have any long-term adverse effects on children. This information will be useful for gaining approval for larger studies to see if pravastatin is actually useful in preventing preeclampsia.
Link: https://pubmed.ncbi.nlm.nih.gov/36842489/
Citation: Costantine MM, Clifton RG, Boekhoudt TM, Lawrence K, Gyamfi-Bannerman C, Wisner KL, Grobman W, Caritis SN, Simhan HN, Hebert MF, Longo M, Saade GR; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and the Obstetric-Fetal Pharmacology Research Centers Network. Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero. Am J Obstet Gynecol. 2023 Feb 24:S0002-9378(23)00111-4. doi: 10.1016/j.ajog.2023.02.016. Epub ahead of print. PMID: 36842489.
Each quarter, our team of science writers reviews the most current research studies related to hypertensive disorders of pregnancy and summarizes those studies of greatest interest and potential impact to our community, including research studies related to risk assessment, diagnosis, prevention, and treatment. Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible, and to our Patient Advisory Council, who reviews these materials from the patient perspective.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of...
A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may b...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...
Current Status and Prospects of the Single-Cell Sequencing Technologies for Revealing the Pathogenesis of Pregnancy-Associated Disorders The adult human body is made up of about 100 trillion cells. I...